Armata posts Q2 net income $74.1M on non-cash gain; AP-SA02 Phase 3 on track

Armata Pharmaceuticals, Inc.

Q2 2026 net income $74.1M vs net loss $16.3M in 2025; basic EPS $2.02, diluted loss $0.27.
Operating loss $10.3M vs $6.8M; R&D $7.6M, G&A $5.2M; grant revenue $2.5M.
Received $2.5M additional DoW funding, total $28.7M; cash $24.0M vs $8.7M at end-2025.
FDA granted Fast Track designation for AP-SA02; Phase 3 protocol submitted; Agreed iPSP obtained.
Promoted David House to CFO; appointed Daniel B. Gilmer, Ph.D. to board of directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.